Healthcare providers can begin CIZ1B ordering setup through a provider onboarding process. Learn who can order CIZ1B, how setup works, and what happens next.

Lung cancer is the leading cause of cancer-related deaths, but early detection can make a meaningful difference. This article explains who may qualify for lung cancer screening, which risk factors to discuss with a healthcare provider, and how Cizzle Bio’s CIZ1B biomarker blood test may help support earlier detection alongside existing screening tools.

CIZ1B takes a focused biomarker approach to early lung cancer detection by identifying a specific protein signal produced by lung cancer cells. Learn how this targeted strategy differs from DNA-based cancer blood tests and why earlier detection matters.

Lung cancer often develops without clear symptoms in its earliest stages, which is why awareness and early detection are so important. Learn about common risk factors, symptoms to watch for, recommended screening guidelines, and why finding lung cancer early can help save lives.

Emerging research indicates smoking history may affect lung cancer outcomes even within the same stage. Learn what this could mean for patients and clinicians, and why earlier detection remains critical.

Lung cancer is often linked to a mix of risk factors, some preventable and others environmental. Learn the leading causes, what you can do to reduce exposure, and when screening may be appropriate.

Lung cancer screening rates remain dangerously low, with fewer than one in five eligible adults getting screened. New national studies show how many lives could be saved through expanded screening and more accessible tools such as the CIZ1B biomarker blood test. This article breaks down the latest data and why early detection solutions are urgently needed.

While smoking remains the leading cause of lung cancer, tens of thousands of people who have never smoked are diagnosed each year. Learn about other risk factors—like radon, air pollution, and genetics—and how early detection can save lives.

Lung cancer isn’t just a disease of older smokers. Cases are rising among young patients—especially women—who often face delayed diagnoses. Discover how early detection with CIZ1B can change outcomes.

Radon is an invisible threat that can raise your risk of lung cancer. This article explains how radon enters homes, why it is hard to detect, which action levels the EPA recommends, and practical steps for testing and mitigation. Learn how awareness and early detection protect families.

Wildfire smoke is more than a nuisance—it’s a serious health threat linked to lung cancer. Discover how Cizzle Bio’s CIZ1B test supports early detection for at-risk populations.

The American Lung Association is pushing for policy changes to expand insurance coverage for biomarker testing in lung cancer. Learn how Cizzle Bio is advancing early detection through its CIZ1B biomarker test.

Lung cancer is the leading cause of cancer-related deaths, but early detection can significantly improve survival rates. Discover how screening, including Cizzle Bio’s CIZ1B Biomarker Test, helps detect lung cancer in its earliest stages—when treatment is most effective.

Lung cancer often goes unnoticed until advanced stages. Learn how early detection with Cizzle Bio’s CIZ1B Biomarker Test can save lives and improve survival rates.

Lung cancer remains the leading cause of cancer deaths, but early detection offers hope. Discover how Cizzle Bio’s CIZ1B biomarker is revolutionizing diagnostics with non-invasive, accurate solutions.

Lung cancer affects one in six Americans and is the leading cause of cancer deaths. Learn about the critical importance of screenings and how Cizzle Bio, Inc. is pioneering early detection with innovative biomarker tests.

Discover the crucial role of lung cancer screening in early detection and improved survival rates. Learn about eligibility, benefits, risks, and the screening process to make informed decisions about your health.

Recent research highlights the ongoing challenges in lung cancer screening across the US, revealing low uptake rates and significant disparities. Cizzle Bio, Inc. is committed to addressing these challenges with our innovative CIZ1B biomarker test.

Delve into the significant barriers that hinder effective lung cancer screening and discover the strategies proposed to overcome these challenges to ensure early detection and better patient care.

Discover key insights on lung cancer from MD Anderson, including types, symptoms, risk factors, and treatment options. Learn why early detection and a multidisciplinary approach are crucial for effective treatment. Read more on MD Anderson's website.